Genmab — September 2019

[peter12]

Måske vi kan forvente de samme gode resultater med TV + keytruda ?

[gentogen]

Nyt studie: The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) and schedules for each combination (combination 1: daratumumab and JNJ-64407564 [anti-GPRC5DxCD3] or combination 2: daratumumab and JNJ-64007957 [anti-BCMAxCD3]) and to characterize the safety of each RP2D for each combination

[gentogen]

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myelom

[gentogen]

https://clinicaltrials.gov/ct2/show/NCT04108195?term=jnj+bispecific&draw=1&rank=2

[E_L]

wow, cool!

[Bulder]

about time!

[Bulder]

The two duobodies are in ph 1 as mono. Have we seen safety data from them?

[Bulder]

Both duobodies are being tested mono as sc as well as IV. But in the combo with dara only as IV.

[E_L]

no i dont think we have. We recently saw this poster on preclinical resutlts, but hard to read
https://twitter.com/ChristieVerkle1/status/1172721173546725376/photo/1

[E_L]

this one also doubled Enrollment earlier this month, which i already thought was a good sign

[E_L]

(clinicaltrials.gov)

[Bulder]

They have Primary Completion Date later this year or next year. So maybe they have seen satisfying safety results already.

[E_L]

the BCMA CD3 also doubled https://clinicaltrials.gov/ct2/history/NCT03145181?A=17&B=18&C=merged#StudyPageTop

[Bulder]

Could have been interesting with dara sc and a duobody sc as well.

[E_L]

sorry, not doubled, but increased

[E_L]

that can still come Bulder

[E_L]

this could turn out to be a great move by JNJ. 1 package JNJ solution.

[Bulder]

agree

[Bulder]

But genmab doesn't get as much royalty from the duobodies? Was it 7%?

[Solsen]

Very good for Genmab if they turns out
to be positve combinations